Sarepta Therapeutics (SRPT)
(Delayed Data from NSDQ)
$15.91 USD
-0.51 (-3.11%)
Updated Aug 1, 2025 04:00 PM ET
After-Market: $15.95 +0.04 (0.25%) 7:58 PM ET
4-Sell of 5 4
C Value F Growth F Momentum F VGM
Fundamental Charts
About Return on Equity (TTM)
Sarepta Therapeutics, Inc.'s return on equity, or ROE, is -14.88% compared to the ROE of the Medical - Biomedical and Genetics industry of -62.65%. While this shows that SRPT has struggled to make solid use of its equity, this metric will vary significantly from industry to industry.
Return on Equity (or ROE) is calculated as income divided by average shareholder equity (past 12 months, including reinvested earnings). The income number is listed on a company's Income Statement. Shareholder Equity (which is the difference between Total Assets and Total Liabilities) can be found on the Balance Sheet.
SRPT 15.91 -0.51(-3.11%)
Will SRPT be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for SRPT based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for SRPT
Will Insmed (INSM) Report Negative Earnings Next Week? What You Should Know
Sarepta Therapeutics (SRPT) to Report Q2 Results: Wall Street Expects Earnings Growth
SRPT: What are Zacks experts saying now?
Zacks Private Portfolio Services
SRPT Slides on Voluntary US Elevidys Shipment Pause Amid Scrutiny
SRPT Down After Third Death in Muscular Dystrophy Gene Therapy Program
SRPT Stock Soars on Unveiling New Restructuring Plan, Pipeline Pivots
Other News for SRPT
Notable analyst calls this week: Nike, Microsoft and Sarepta among top picks
EXCLUSIVE: July's 20 Most-Searched Tickers On Benzinga Pro — Where Do Opendoor, Nvidia, Apple Stock Rank?
Buy/Sell: Wall Street's top 10 stock calls this week
SRPT September 12th Options Begin Trading
Sarepta Therapeutics to Announce Second Quarter 2025 Financial Results | SRPT Stock News